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Abstract
Background: The reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) down-regulation has been confirmed in
numerous human cancers and is clinically associated with metastasis. This study investigates the potential associations of
RECK single-nucleotide polymorphisms (SNPs) with hepatocellular carcinoma (HCC) susceptibility and its clinicopathologic
characteristics.
Methodology/Principal Findings: A total of 135 HCC cancer patients and 501 cancer-free controls were analyzed for four
RECK SNPs (rs10814325, rs16932912, rs11788747, and rs10972727) using real-time PCR and PCR-RFLP genotyping analysis.
After adjusting for other co-variants, the individuals carrying RECK promoter rs10814325 inheriting at least one C allele had
a 1.85-fold [95% confidence interval (CI), 1.03–3.36] risk of developing HCC compared to TT wild type carriers. The HCC
patients, who carried rs11788747 with at least one G allele, had a higher distant metastasis risk than wild type probands.
Conclusions: RECK gene polymorphisms might be a risk factor increasing HCC susceptibility and distant metastasis in
Taiwan.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer worldwide, with 750 000 newly diagnosed cases in 2008.
HCC is the third most common cause of cancer mortality [1].
Taiwan has the third highest incidence area in the world, with a
35.7/10
5 age-standardized rate in 2008. HCC was the leading
cause of cancer death among men, with a mortality of 39.3/10
5,
and the second among women, with mortality of 14.7/10
5 in 2008
[2]. The development of HCC is a multistep and complex process.
Multiple environmental risk factors, including chronic hepatitis B
virus (HBV) or hepatitis C virus (HCV) infection, cirrhosis,
carcinogen exposure, and a variety of genetic factors contribute to
hepatocarcinogenesis [3,4]. Cumulative studies have suggested the
associations between HCC cancer risk and SNPs in selected
candidate genes. For example, insulin-like growth factor (IGF)-2,
IGF-2R, plasminogen activator inhibitor (PAI)-1, and matrix
metalloproteinase (MMP) 14 [5–7] are HCC risk factors.
The reversion-inducing-cysteine-rich protein with Kazal motifs
(RECK) gene is a novel transformation suppressor gene against
activated ras oncogenes, and induces flat reversion in v-K-ras-
transformed NIH/3T3 cells [8,9]. The RECK gene encodes a
membrane-anchored glycoprotein that can negatively regulate
matrix metalloproteinases (MMPs) and inhibit tumor invasion,
angiogenesis, and metastasis. RECK-expressing tumors show a
significant reduction in microvessel density and branching, and
result in tumor tissue death in mice [8,10]. RECK down-
regulation or promoter hypermethylation have been confirmed
in many human cancers, including pancreatic cancer, breast
cancer, lung cancer, colorectal cancer, cholangiocarcinoma,
gastric cancer, prostate cancer, oral cancer, esophageal cancer,
and osteosarcoma, and correlated with tumor metastasis or poor
prognosis [11–23].
A previous study showed high RECK mRNA expression in
HCC tumor tissues from patients with better survival and less
invasive clinicopathologic features [24]. However, to our knowl-
edge, no study has investigated the role of RECK gene variants in
HCC development and clinical factors. This study performs a
case-control study for four SNPs located in the promoter or exon
regions of the RECK gene (Fig. 1) to analyze the associations
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clinicopathologic characteristics
Materials and Methods
Study subjects and specimen collection
The present hospital based case-control study recruited 135
HCC patients between 2007 to 2010 in Chung Shan Medical
University Hospital, Taiwan. The diagnosis of HCC was
according to the characteristic criteria of the national guidelines
for HCC, such as liver tumor tissue diagnosed by histology or
cytology irrespective of a-fetoprotein (AFP) titer where imaging
data, either computed tomography or magnetic resonance
imaging, showed one of following three cases: (1) One or more
liver masses §2 cm in diameter; (2) One imaging data with early
enhancement and a high level of AFP §400 ng/mL; (3) One
imaging data with early arterial phase contrast enhancement plus
early venous phase contrast washout. Meanwhile, 501 race- and
ethnic group-matched non-cancer evidence community residents
who entered the hospital for health check-ups were enrolled as the
control group.
HCC patients were staged clinically at the time of diagnosis
according to the TNM staging system of the American Joint
Committee on Cancer (AJCC) (2002) [25]. Liver cirrhosis was
diagnosed with liver biopsy, abdominal sonography, or biochem-
ical evidence of liver parenchymal damage with endoscopic
esophageal or gastric varices. The patients’ clinicopathological
characteristics, such as clinical staging, tumor size, lymph node
metastasis, distant metastasis, hepatitis B surface antigen (HBsAg),
antibody to HCV (anti-HCV), liver cirrhosis, AFP, aspartate
aminotransferase (AST) and alanine aminotransferase (ALT), were
verified by chart review. The whole blood specimens collected
from healthy controls and HCC patients, were placed in tubes
containing ethylenediaminetetraacetic acid (EDTA) and immedi-
ately centrifuged and stored at 280uC. Before the conduction of
this study, approval from the Institutional Review Board of Chung
Shan Medical University Hospital was obtained, and informed
written consent was obtained from each individual.
Genomic DNA extraction
Genomic DNA was extracted by QIAamp DNA blood mini kits
(Qiagen, Valencia, CA) according to the instructions of manufac-
turer. DNA was dissolved in TE buffer [10 mM Tris (pH 7.8),
1 mM EDTA] and then quantified by a measurement of OD260.
Final preparation was stored at 220uC and used as templates for
polymerase chain reaction (PCR).
Polymerase chain reaction-restriction fragment length
polymorphism
The RECK rs16932912, rs11788747 and rs10972727 gene
polymorphisms were determined by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) assay as
previously described [21]. The primer sequences and restriction
enzyme for analysis of the RECK gene polymorphisms are
described in Table 1. The PCR was performed in a 10 mL volume
containing 100 ng DNA template, 1.0 mLo f1 0 6 PCR buffer
(Invitrogen, Carlsbad, CA), 0.25 U of Taq DNA polymerase
(Invitrogen, Carlsbad, CA), 0.2 mM dNTPs (Promega, Madison,
WI), and 200 nM of each primer (MDBio Inc, Taipei, Taiwan).
The PCR cycling conditions were 5 min at 94uC followed by 35
cycles of 1 min at 94uC, 1 min at 60uC, and 2 min at 72uC, with a
final step at 72uC for 20 min. Ten ml aliquot of PCR product was
subjected to digestion at 37uC for 4 h in a 15 mL reaction buffer
containing 1.5 mL1 0 6buffer (New England Biolabs) and 5 U of
TfiI, RsaI and HpyCH4IV (New England Biolabs, Beverly, MA) for
RECK rs16932912, rs11788747 and rs10972727, respectively. To
validate results from PCR-RFLP, around 10% of assays were
repeated and several cases of each genotype were confirmed by the
DNA sequence analysis.
Real-time PCR
The allelic discrimination of the RECK rs10814325 gene
polymorphisms was assessed with the ABI StepOne
TM Real-Time
PCR System (Applied Biosystems) and analyzed using SDS v3.0
software (Applied Biosystems), using the TaqMan assay (assay IDs:
C_27084758_10). The final volume for each reaction was 5 mL,
containing 2.5 mL TaqMan Genotyping Master Mix, 0.125 mL
Figure 1. The location of human RECK gene single-nucleotide polymorphisms (SNPs) and functional amino acid.
doi:10.1371/journal.pone.0033517.g001
Table 1. Primer sequences and PCR-RFLP conditions for
amplification of RECK SNPs.
SNP Sequences Product Enzyme
RECK
rs16932912
59-TGGAGATTGTTGATGGTCTC-3
59-CGGTACACAATGCTCAATAC-39
G/G: 353 bp
A/A: 250 bp,
103 bp
TfiI
RECK
rs11788747
59-GTAGAAGAAGTGACTCATCC-3
59-ATCTCACTCCGAAGATAACC-39
A/A: 242 bp
G/G: 140 bp,
102 bp
RsaI
RECK
rs10972727
59-TTCTGTCAGGTCATGGAACA-39
59-TGCAGTTAAGACTGGAGAAG-39
T/T: 224 bp
A/A: 119 bp,
105 bp
HpyCH4IV
doi:10.1371/journal.pone.0033517.t001
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PCR reaction included an initial denaturation step at 95uC for
10 min, followed by 40 cycles, each consisting of 95uC for 15 sec
and 60uC for 1 min.
Statistical analysis
Hardy–Weinberg equilibrium was assessed using a chi-square
goodness-of-fit test for biallelic markers. A Mann–Whitney U-test
and a Fisher’s exact test were used to compare the differences of
age as well as demographic characteristics distributions between
controls and HCC patients. The adjusted odds ratio (AOR) with
their 95% confidence intervals (CIs) of the association between
genotype frequencies and HCC risk as well as clinical pathological
characteristics were estimated by multiple logistic regression
models after controlling for other covariates, A p value,0.05
was considered significant. Rs10814325 SNP was predicted to
change transcription factor binding sites by TRANSFAC (URL:
http://thr.cit.nih.gov/molbio/signal/) [12]. The data were ana-
lyzed on SAS statistical software (Version 9.1, 2005; SAS Institute
Inc., Cary, NC).
Results
This study analyzes the demographic characteristics of sample
specimens and found that 41.9% (210 of 501) and 34.8% (47 of
135) of healthy control subjects and patients with HCC,
respectively, who had consumed alcohol; 41.1% (206 of 501)
and 40.7% (55 of 135) of healthy controls and patients with HCC,
respectively, had smoked. The distributional differences of alcohol
(p=.136) and tobacco consumption (p=.937) between healthy
controls and patients with HCC were insignificant, whereas age
distribution (control: 52.9614.48; HCC: 64.24611.08) (p,.001)
and gender distribution (p,.001) between the 2 subgroups were
significantly different (Table 2). To reduce the possible interfer-
ence of the confounding variables, we used adjusted odds ratios
(AORs) with 95% confidence intervals (CIs) were estimated by
multiple logistic regression models after controlling for age and
gender in each comparison. Table 3 shows the genotype
distributions and the association between HCC and gene
polymorphisms of RECK. The alleles with the highest distribution
frequency for rs10814325, rs16932912, rs11788747, and
rs10972727 genes of RECK in both recruited HCC patients and
healthy controls were heterozygous T/C, homozygous G/G,
homozygous A/A, and homozygous T/T, respectively. After
adjusting variables, people with rs10814325 TC, CC, TC+CC
showed a 2.112-fold (95% CI: 1.108–4.028), 2.184-fold (95%CI:
1.211–3.939), or 1.85-fold (95%CI: 1.027–3.361) higher risk of
HCC compared to wild type individuals. People with rs16932912,
rs11788747, and rs10972727 genes of RECK polymorphism
showed no higher risk of HCC compared to wild type individuals.
The distribution frequency of clinical statuses and RECK
genotypes frequencies in HCC patients were estimated to clarify
the role of RECK gene polymorphisms in the clinicopathologic
states of HCC patients, including TNM clinical staging, primary
tumor size, lymph node involvement, distant metastasis, hepatitis
B surface antigen (HBsAg), antibody to HCV (anti-HCV), and
liver cirrhosis. There was no observed significant association
between the rs10814325, rs16932912, and rs10972727 gene
polymorphisms and clinicopathologic states. However, among
HCC patients, those who had rs11788747 SNPs also had a higher
risk of distant metastasis (p=.003) than wild type patients (Table 4),
but no difference existed in HBsAg, anti-HCV, Child-Pugh grade
or liver cirrhosis (Table 5).
AFP, AST, and ALT are common clinical pathological markers
of HCC. To clarify the relationship between the progress of
clinical status and the level of clinical pathological markers in
HCC patients, this study also analyzes the levels of these
pathological markers associated with RECK genotypic frequen-
cies. Table 6 shows that the levels of ALT were significantly
different between the rs11788747 AA and AG/GG genotypes
(p,.05).
Discussion
This study provides novel information on the effects of single-
nucleotide polymorphisms of RECK on HCC susceptibility and
clinicopathologic status association. The genomic structure for the
RECK gene has been identified on the chromosome region
9p13Rp12. The RECK gene includes 21 exons and 20 introns,
and 13 SNPs were identified [26]. Among 13 SNPs, rs16932912,
rs11788747, and rs10972727 were found within the coding
sequence in exons 9, 13, and 15, respectively [26]. These
polymorphisms are non-synonymous and changed amino acid
sequence as well as RECK protein structure. For example, Valine
changes to Lysine in rs16932912 SNP. Rs10814325 SNP was
located at promoter sites and was predicted to change transcrip-
tion factor binding sites by TRANSFAC [12]. Although the
functional importance of rs10814325 SNPs has not been tested
experimentally, clinical research from Germany shows that breast
cancer patients carrying rs10814325 -402 T/C SNP have a
greater chance of survival than those carrying T/T wild type [12].
In the present study, individuals carrying the RECK promoter
rs10814325 inheriting at least one C allele had a 1.85-fold higher
risk of HCC compared to TT wild type carriers. However, no
significant association was present between the rs10814325 gene
polymorphisms and clinicopathologic states. The data are
apparently contradictory in relation to carcinogenesis and
probably survival. However, the potential mechanism and
functional consequences of the promoter sequence change should
be elucidated in the laboratory and clinically as well. Meanwhile,
in this study, the frequencies of rs10814325 T/T, T/C and C/C
were 28.5%, 44.9% and 26.5%, respectively. However, in
Table 2. The distributions of demographical characteristics in
501 healthy controls and 135 patients with HCC.
Variable
Controls
(N=501)
Patients
(N=135) p value
Age (yrs) Mean ± S.D. Mean ± S.D.
52.9614.48 64.24611.08 P,0.001*
Gender n (%) n (%)
Male 415 (82.8%) 92 (68.1%)
Female 86 (17.2%) 43 (31.9%) p,0.001*
Alcohol consumption
No 291 (58.1%) 88 (65.2%)
Yes 210 (41.9%) 47 (34.8%) p=0.136
Tobacco consumption
No 295 (58.9%) 80 (59.3%)
Yes 206 (41.1%) 55 (40.7%) p=0.937
Mann-Whitney U test or Fisher’s exact test was used between healthy controls
and patients with HCC.
*, p value,0.05 as statistically significant.
doi:10.1371/journal.pone.0033517.t002
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T/C and C/C were 83.7%, 15.8% and 0.5%, respectively [12].
Obviously, there is an ethnicity-related variation in the frequency
of rs10814325 polymorphisms. The contradictory findings of
previous research may be the result of the different ethnic
backgrounds of patients.
This study shows that individuals carrying the RECK promoter
rs10814325 polymorphism have a 1.85-fold risk of developing
Table 3. Adjusted odds ratio (AOR) and 95% confidence interval (CI) of HCC associated with RECK genotypic frequencies.
Variable Controls (N=501) n (%) Patients (N=135) n (%) OR (95% CI) AOR (95% CI)
rs10814325
TT 143 (28.5%) 21 (15.6%) 1.00 1.00
TC 225 (44.9%) 72 (53.3%) 2.179 (1.283–3.700) 2.11 (1.11–4.03)
CC 133 (26.5%) 42 (31.1%) 2.150 (1.211–3.820) 2.18 (1.21–3.94)
TC+CC 358 (71.5%) 114 (84.4%) 2.168 (1.310–3.590) 1.85 (1.03–3.36)
rs16932912
GG 272 (54.3%) 64 (47.4%) 1.00 1.00
GA 192 (38.3%) 57 (42.2%) 1.262 (0.844–1.886) 1.41 (0.88–2.27)
AA 37 (7.4%) 14 (10.4%) 1.608 (0.821–3.151) 1.81 (0.75–4.37)
GA+AA 229 (45.7%) 71 (52.6%) 1.318 (0.900–1.928) 1.48 (0.94–2.33)
rs11788747
AA 281 (56.1%) 83 (61.5%) 1.00 1.00
AG 192 (38.3%) 41 (30.4%) 0.723 (0.477–1.097) 0.66 (0.40–1.07)
GG 28 (5.6%) 11 (8.1%) 1.330 (0.635–2.785) 1.27 (0.51–3.16)
AG+GG 220 (43.9%) 52 (38.5%) 0.800 (0.542–1.181) 0.74 (0.47–1.17)
rs10972727
TT 279 (55.7%) 76 (56.3%) 1.00 1.00
TA 191 (38.1%) 54 (40.0%) 1.038 (0.700–1.540) 1.03 (0.64–1.64)
AA 31 (6.2%) 5 (3.7%) 0.592 (0.223–1.575) 0.48 (0.16–1.46)
TA+AA 222 (44.3%) 59 (43.7%) 0.976 (0.665–1.431) 0.96 (0.61–1.51)
The odds ratios (ORs) with their 95% confidence intervals were estimated by logistic regression models.
The adjusted odds ratios (AORs) with their 95% confidence intervals were estimated by multiple logistic regression models after controlling for age, gender, alcohol and
tobacco consumption.
doi:10.1371/journal.pone.0033517.t003
Table 4. Clinical TNM staging and RECK genotypic frequencies in 135 HCC patients.
Variable rs10814325 rs16932912 rs11788747 rs10972727
TT
(N=21)
TC+CC
(N=144) p value
GG
(N=64)
GA+AA
(N=71) p value
AA
(N=83)
AG+GG
(N=52) p value
TT
(N=76)
TA+AA
(N=59) p value
n( % ) n( % ) n( % ) n( % ) n( % ) n( % ) n( % ) n( % )
Clinical stage
Stage I/II 12 (57.1%) 72 (63.2%) 0.601 38 (59.4%) 46 (64.8%) 0.517 54 (65.1%) 30 (57.7%) 0.390 49 (64.5%) 35 (59.3%) 0.540
Stage III/IV 9 (49.2%) 42 (36.8%) 26 (40.6%) 25 (35.2%) 29 (34.9%) 22 (42.3%) 27 (35.5%) 24 (40.7%)
Tumor size
y
T2 13 (61.9%) 72 (64.9%) 0.791 41 (64.1%) 46 (64.8%) 0.930 55 (66.3%) 32 (61.5%) 0.577 51 (67.1%) 36 (61.0%) 0.464
.T2 8 (38.1%) 42 (35.1%) 23 (35.9%) 25 (35.2%) 28 (33.7%) 20 (38.5%) 25 (32.9%) 23 (39.0%)
Lymph node
metastasis
No 19 (90.5%) 109 (95.6%) 0.298 60 (93.8%) 68 (95.8%) 0.442 79 (95.2%) 49 (94.2%) 0.550 72 (94.7%) 56 (94.9%) 0.639
Yes 2 (9.5%) 5 (4.4%) 4 (6.3%) 3 (4.2%) 4 (4.8%) 3 (5.8%) 4 (5.3%) 3 (5.1%)
Distant metastasis
No 19 (90.5%) 110 (96.5%) 0.235 59 (92.2%) 70 (98.6%) 0.082 83 (100.0%) 46 (88.5%) 0.003* 75 (98.7%) 54 (91.5%) 0.057
Yes 2 (9.5%) 4 (3.5%) 5 (7.8%) 1 (1.4%) 0 (0%) 6 (11.5%) 1 (1.3%) 5 (8.5%)
*p value,0.05.
doi:10.1371/journal.pone.0033517.t004
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administration of black-tea polyphenon-B significantly reduces the
incidence of dimethylaminoazobenzene (DAB)-induced hepato-
mas as evidenced by modulation of RECK, matrix metallopro-
teinase (MMP)-2, MMP-9, and the tissue inhibitor of matrix
metalloproteinase-2 [27]. The alternation of RECK promoter
affinity and RECK expression is likely the result of activating the
extracellular signal-regulated kinase (ERK) pathway [28,29]. In a
human model, up-regulation of the mitogen-activated protein
kinase (MAPK) pathway and genes is associated with an activated
cell cycle and may be of critical importance to the formation and
maintenance of hepatocellular carcinoma [30,31]. These findings
might be the molecular hepatocarcinogenesis of RECK, but the
mechanism should be elucidated in laboratory and clinical settings.
This study shows that HCC patients carrying rs11788747
polymorphisms had a higher risk of distant metastasis (p=.003)
than wild type carriers. Previous research confirms the relation-
ships of RECK expression and gene status with tumor metastasis.
Using Matrigel invasion chamber assay in vitro and in
experimental and spontaneous metastasis assays in vivo, the
experiments in this study artificially restored RECK expression in
tumor cells (such as HT1080 fibrosarcoma or B16 melanoma), in
which endogenous RECK was undetectable. This approach
greatly suppresses their invasive and metastatic potentials [8].
Low RECK expression colorectal cancer and esophageal cancer
patients exhibited more lymph node metastasis [14,32]. In non-
small cell lung cancer patients, RECK promoter methylation has a
higher incidence of lymph node metastasis [33]. In betel quid-
chewing oral cancer patients, those who have the RECK
rs10814325 polymorphism have a higher risk of neck lymph node
metastasis than wild type carriers [21].
This is the first study to associate the RECK gene polymor-
phisms with risk of HCC. Results showed RECK promoter SNP
individuals increase HCC susceptibility, and rs11788747 poly-
morphism HCC patients had a higher risk of distant metastasis.
These findings suggest that RECK plays a role in HCC
carcinogenesis and metastasis. However, the number of case and
control people in this study was relatively small. Additional studies
with larger sample sizes are needed to validate the genetic effects of
the RECK polymorphisms on HCC. Further collection of samples
should investigate the RECK sequence variants and their
biological function in Taiwanese HCC patients.
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Table 5. Clinical status and RECK genotypic frequencies in 135 HCC patients.
Variable rs10814325 rs16932912 rs11788747 rs10972727
TT
(N=21)
TC+CC
(N=144) p value
GG
(N=64)
GA+AA
(N=71) p value
AA
(N=83)
AG+GG
(N=52) p value
TT
(N=76)
TA+AA
(N=59) p value
n( % ) n( % ) n( % ) n( % ) n( % ) n( % ) n( % ) n( % )
HBsAg
Negative 10 (47.6%) 71 (62.3%) 0.208 37 (57.8%) 44 (62.0%) 0.622 51 (61.4%) 30 (57.7%) 0.665 45 (59.2%) 36 (61.0%) 0.832
Positive 11 (52.4%) 43 (37.7%) 27 (42.2%) 27 (38.0%) 32 (38.6%) 22 (42.3%) 31 (40.8%) 23 (39.0%)
Anti-HCV
Negative 8 (38.1%) 55 (48.2%) 0.392 31 (48.4%) 32 (45.1%) 0.695 41 (49.4%) 22 (42.3%) 0.422 41 (53.9%) 22 (37.3%) 0.054
Positive 13 (61.9%) 59 (51.8%) 33 (51.6%) 39 (54.9%) 42 (50.6%) 30 (57.7%) 35 (46.1%) 37 (62.7%)
Child-Pugh grade
A 15 (71.4%) 84 (73.7%) 0.830 49 (76.6%) 50 (70.4%) 0.421 61 (73.5%) 38 (73.1%) 0.957 56 (73.7%) 43 (72.9%) 0.917
B or C 6 (28.6%) 30 (26.3%) 15 (23.4%) 21 (29.6%) 22 (26.5%) 14 (26.9%) 20 (26.3%) 16 (27.1%)
Liver cirrhosis
Negative 5 (23.8%) 30 (26.3%) 0.810 17 (26.6%) 18 (25.4%) 0.873 23 (27.7%) 12 (23.1%) 0.550 21 (27.6%) 14 (23.7%) 0.608
Positive 16 (76.2%) 84 (73.7%) 47 (73.4%) 53 (74.6%) 60 (72.3%) 40 (76.9%) 55 (72.4%) 45 (76.3%)
doi:10.1371/journal.pone.0033517.t005
Table 6. Association of RECK genotypic frequencies with HCC
laboratory status.
Characteristic
a-Fetoprotein
a
(ng/mL)
AST
a
(IU/L)
ALT
a
(IU/L)
AST/ALT
ratio
a
rs10814325
TT 165.8650.6 191.4670.3 128.5624.5 1.3460.18
TC/CC 3999.361542.3 178.7633.6 144.1634.4 1.5360.11
p value 0.289 0.880 0.980 0.465
rs16932912
GG 3582.862169.5 155.4630.7 136.1623.0 1.3560.10
GA/AA 3240.861548.8 203.4650.6 148.9637.7 1.6460.16
p value 0.897 0.431 0.777 0.125
rs11788747
AA 3261.361376.1 220.9646.7 179.4635.2 1.4760.10
AG/GG 3629.162606.0 116.4646.7 84.6613.2 1.5660.19
p value 0.892 0.093 0.040* 0.659
rs10972727
TT 3317.661491.4 225.2650.7 182.1642.5 1.5160.12
TA/AA 3512.962307.8 122.2621.8 95.5613.2 1.4960.16
p value 0.941 0.095 0.052 0.919
Mann-Whitney U test was used between two groups.
aMean 6 S.E.
*p value,0.05.
doi:10.1371/journal.pone.0033517.t006
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